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Abstract
Type 1 diabetes mellitus (DM) is characterized by autoimmune aggression against pancreatic beta cells resulting in absolute
deficiency of insulin secretion. The first detectable sign of emerging autoimmunity during the preclinical asymptomatic
period is the appearance of diabetes-related autoantibodies. In children at risk for type 1 DM, high-affinity Insulin
autoantibodies reactive to proinsulin, are associated with diabetes risk. Autoantibodies are usually measured by radioligand
binding assay (RBA) that provides quasi-quantitative values reflecting potency (product between concentration and affinity)
of specific autoantibodies. Aiming to improve the characterization of the specific humoral immune response, we selected
surface plasmon resonance (SPR) as an alternative method to measure proinsulin autoantibodies (PAA). This novel
technology has allowed real time detection of antibodies interaction and kinetic analysis. Herein, we have employed SPR to
characterize the PAA present in sera from 28 childhood-onset (mean age 8.3164.20) and 23 adult-onset diabetic patients
($65 years old, BMI,30) in terms of concentration and affinity. When evaluating comparatively samples from both groups,
childhood-onset diabetic patients presented lower PAA concentrations and higher affinities (median 67.12610
29 M and
3.50610
7 M
21, respectively) than the adults (median 167.4610
29 M and 0.84610
7 M
21, respectively). These results are
consistent with those from the reference method RBA (Standard Deviation score median 9.49 for childhood-onset group
and 5.04 for adult-onset group) where the binding can be directly related to the intrinsic affinity of the antibody, suggesting
that there is a different etiopathogenic pathway between both types of clinical presentation of the disease. This technology
has shown to be a useful tool for the characterization of PAAs parameters as an alternative to radioimmunoassay, with high
versatility and reproducibility associated to low occupational and environmental risk. However, this technology is not
eligible for routine marker screening, but this is a powerful technique for a fine description of the thermodynamic
parameters of antigen-antibody interaction.
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Introduction
Type 1 diabetes mellitus (DM) is characterized by autoimmune
aggression against pancreatic beta cells resulting in absolute
deficiency of insulin secretion, and by its association with certain
high-susceptibility HLA alleles. The first detectable sign of
emerging beta cell autoimmunity during the preclinical asymp-
tomatic period is the appearance of diabetes-related autoantibod-
ies. On the other hand, type 2 DM occurs later in life and is
characterized by insulin resistance and/or inadequate compensa-
tory insulin secretion. Some adult patients with a phenotype of
type 2 DM elicit antibodies directed against islet beta cell antigens.
These patients, who slowly progress to insulin deficiency, are
considered to have slow-onset or latent autoimmune diabetes
(LADA) [1].
During the natural history of childhood diabetes, insulin and
proinsulin autoantibodies (IAA/PAA) are often the first markers
detected early in infancy [2,3,4,5]. Many, but not all, IAA-positive
children also develop autoantibodies to other beta cell antigens
[3,4,6,7]. Children who develop these additional antibodies
usually progress to clinical type 1 DM, whereas those who remain
positive only for IAA rarely develop the disease [3]. Therefore,
development of multiple islet autoantibodies is an important
feature in the pathogenesis of DM.
Achenbach et al. described in children at risk for type 1 DM,
that high affinity IAA were associated with HLA DRB1*04, young
age of IAA appearance, and subsequent progression to multiple
islet autoantibodies or type 1 DM. In addition, high affinity IAA
were reactive against proinsulin indicating that type 1 DM is
associated with sustained early exposure to proinsulin in the
context of HLA DR4, and showing that high-affinity proinsulin-
reactive IAA identify children with the highest diabetes risk [8].
Conventionally, IAA/PAA are measured by radioligand
binding assay (RBA), which requires radiolabeled antigen and
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incubation) to achieve higher signals. The quasi-quantitative
values yielded by this method [9] reflect the influence of antibody
concentration and affinity [10].
Aiming to characterize the specific humoral immune response
against proinsulin, we selected surface plasmon resonance (SPR) as
an alternative method to measure PAA through the assessment of
antigen-antibody interaction parameters. It is important to note
that in SPR assays such interaction can be expressed in terms of
kinetic association (k1) and dissociation (k21) rates besides the
equilibrium affinity constant (Ka). In contrast, in RBA only bound
percent (B%) signals are reported, and only in selected studies
affinity constants are estimated from displacement radioimmuno-
assays (RIA) [8].
Some type 1 DM-related autoantibodies have been previously
measured by SPR. For example Ayela et al. [11] quantified
autoantibodies to tyrosine phosphatase IA-2, and Carlsson et al.
[12] described an indirect competitive immunoassay for detection
and relative quantification of IAA. However there are no reports
on both concentration and affinity assessment for IAA/PAA in
patients’ sera using the SPR technique.
The aim of this work was to use this novel technology to
characterize the concentration and affinity of PAA present in sera
from both childhood-onset and adult-onset diabetic patients with
two alternative forms of proinsulin antigen: the genuine unmod-
ified proinsulin (PI) and the recombinant chimeric thioredoxin-
proinsulin (TrxPI) constructed in our laboratory [13]. The
intention of this approach was to improve the orientation of PI
assuring that all epitopes could be better exposed to antibodies.
The final purpose was to further define the quantitative pattern of
PAA response in rapid and slowly progressive forms of
autoimmune diabetes otherwise well characterized in terms of
clinical presentation, markers profile [14] and genetic susceptibility
background [15].
Methods
Samples from diabetic patients
All samples from 51 selected diabetic patients that were
included in this study spanned a wide range of PAA positivity.
Sera from 28 children and adolescents admitted to the Nutrition
Service at the J. P. Garrahan Pediatric Hospital (Buenos Aires,
Argentina), with a mean age of 8.3164.20 at diagnosis were
collected before or within 72 h of insulin treatment initiation.
Type 1 diabetes was diagnosed according to WHO criteria [16].
The starting group included 71 children and adolescents attending
the service from June 1994 to July 1996. As the hospital is a
referral centre, patients came from all over Argentina and were
mainly Caucasians. All these patients were tested in parallel for
diabetic humoral markers, PAA, glutamic acid decarboxylase
autoantibodies (GADA), protein tyrosine phosphatase IA-2
autoantibodies (IA-2A) and autoantibodies to zinc transporter 8
(ZnT8A). Most patients, 71.8%, were GADA+, the second marker
in frequency was ZnT8A (69.0%), 66.2% were IA-2A+ and 36.6%
were PAA+.
Sera from 23 elderly subjects attending the Diabetes Division at
the Jose ´ de San Martı ´n Clinical Hospital (Buenos Aires,
Argentina), with diabetes diagnosed at $65 years old and body
mass index (BMI) ,30 were included. These sera were selected
from a starting population of 68 subjects attending the Diabetes
Division from 2010 to 2011. All these adult-onset diabetic patients
were tested in parallel for all the mentioned humoral markers. Out
of these patients, 60.0% presented at least one humoral marker,
38.5% were GADA+, 1.5% were IA-2A+, 16.9% were ZnT8A+
and 32.3% were PAA+. Diagnosis was performed according to the
American Diabetes Association [1]. The criteria for oral
hipoglycaemic agent (OHA) therapy were those of the UK
Prospective Diabetes Study [17]. Adult patients included in this
study had not been treated with insulin before blood sample
collection for immunochemical analysis.
Blood samples were collected after overnight fasting and sera
were stored at 220uC until assayed. The collection of serum
samples from newly diagnosed type 1 diabetic patients and adult-
onset diabetic patients, and the respective protocols were approved
by the Ethical Committees of the J. P. Garrahan National
Pediatric Hospital and Jose ´ de San Martı ´n Clinical Hospital,
respectively. Written consent from all participants involved in this
study, and parental consent when being a minor, was obtained.
Rabbit polyclonal antibodies to proinsulin
High-titered PI antibodies were obtained by immunizing two
New Zealand White rabbits with 0.1 mg of standard human PI
(Eli Lilly, Indianapolis, IN) emulsified in complete Freund’s
adjuvant. The initial injection was followed by booster injections
with 0.1 mg of PI in incomplete adjuvant at three-week intervals.
Rabbits were bled 15 days after the last boosting. They were
maintained in a specific pathogen–free facility and treated with
Figure 1. Dose-response curves obtained by using rabbit anti-
human-PI serum and standard PI in a fluid phase displacement
experiment incubated until reaching equilibrium. The parameter
1/K0 was calculated by interpolation at (B/F)0/2 in the upper graphic [B/
F=f(log F)]. In the lower graphic representing B/F=f(log dose) the (B/
F)0/2 intercepts the abscisa axis at 1/K0+q0/2 [21].
doi:10.1371/journal.pone.0033574.g001
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Committee of the University of Buenos Aires.
PAA detection by Radioligand Binding Assay (RBA)
Sera from diabetic patients were first subjected to RBA to detect
the presence of PAA. Those positive sera were then used for SPR
analysis in order to characterize their concentration and affinity
parameters.
RBA for PAA was performed as previously described [18].
Briefly, cDNA coding for human PI was transcribed and translated
using a rabbit reticulocyte lysate system in the presence of
[
35S]cysteine (New England Nuclear, Boston, MA), according to
the manufacturer instructions. After overnight refolding, favored
by a disulphide reduction-reoxidation procedure, [
35S]-PI was
isolated by reverse-phase HPLC. Sera (30 ml) were incubated for
seven days at 4uC with 1,000 cpm of [
35S]-PI in 90 ml of RBA
buffer (50 mM sodium phosphate, 100 mM NaCl, pH 7, 0.1%
Aprotinin and 0.1% bovine serum albumin). Subsequently, 50 ml
of a 50% suspension of Protein G-Sepharose 4B FF (Amersham
Biosciences, Piscataway, NJ) in RBA buffer were added, in order
to isolate the immunocomplexes. Samples were centrifuged and
supernatants were discarded. Pellets were washed four times with
200 ml of RBA buffer, suspended in 100 ml 1% SDS, and
centrifuged (5 min at 6,0006g). Supernatants were carefully
transferred to appropriate vials for scintillation counting, which
was performed at 5 min per tube. Results were calculated as B
%=1006bound cpm/total cpm and expressed as SD score=(B %-
BC %)/SDC, where BC % was the mean B % of control sera and
SDC its standard deviation. An assay was considered positive if SD
score .3. Thirty normal controls were included and BC % was
normally distributed. The intra-assay CVs in triplicates were 10.34
and 3.78% for a SD score of 17.2 and 33.3, respectively.
Fluid phase dose-response curves and data processing
The RIA carried out with the rabbit polyclonal serum against PI
was performed by incubating 30 ml of 1/100 final dilution of this
serum for seven days at 4uC with 1,000 cpm of [
35S]-PI in the
presence of 90 ml of different concentrations of human PI in RBA
buffer. Immunocomplexes were isolated with Protein G-Sepharose
4B FF, the pellets were washed and suspended in 1% SDS.
Radioactivity of supernatants was counted in an automatic beta
counter. Concentration (q0) and median affinity constant (K0)
parameters for the polyclonal rabbit anti-PI serum were derived
from B/F=f (Log F or Log dose) plots [19].
Recombinant Human Proinsulin
Standard PI was a gift from Eli Lilly (Indianapolis, IN). On the
other hand, PI was expressed in E. coli as a fusion protein with
thioredoxin (TrxPI) (Materials and Methods S1) as published
elsewhere [13]. Briefly, E. coli GI 724 transformed with pTrx-PI
were cultured at 30uC in 0.2% casein amino acids, 0.5% glucose,
1 mM MgCl2, and 100 mg/ml ampicillin. Protein expression was
induced with 100 mg/ml tryptophan. Inclusion bodies were
washed with 2 M urea in Tris 0.1 M pH 8.5 and solubilized with
5 M urea in Tris 0.1 M pH 8.5. Oxidative refolding was
performed as described previously [18]. After overnight incubation
for refolding of solubilized inclusion bodies, TrxPI was isolated by
FPLC on a Q-Sepharose column (GE Healthcare, Sweden).
Immobilization of PI or TrxPI for SPR assays
PI or TrxPI immobilization and subsequent interactions
analysis were performed according to the user manual of the
SPR BIAcore T100 biosensor (BIAcore, GE Healthcare, Uppsala,
Sweden). Both proteins were immobilized on a carboxymethylated
dextran sensor surface CM5 chip using conventional carbodiimide
coupling chemistry [20]. The carboxyl groups at the sensor chips
were activated with 0.2 M N-ethyl-N-(3-diethylmiopropyl) carbo-
diimide (EDC) and 0.05 M N-hydroxysuccinimide (NHS) for
7 min. PI and TrxPI diluted at 30 mg/ml in 10 mM acetate buffer
(pH 4.5 and pH 4.0, respectively) were injected for surface
immobilization until 2000 or 500 resonance units (RU) were
obtained for concentration or affinity assay, respectively. The
remaining reactive groups on the surfaces were blocked by
injecting ethanolamine hydrochloride (1 M, pH 8.5, 7 min). The
Figure 2. Calibration curve. (A) Sensorgram and (B) Standard curve of resonance units (RU) vs. antibody concentration as determined with an anti-
human-PI polyclonal serum. The concentration values of polyclonal antibody used in the standard curve were: 75 nM, 37.50 nM, 18.75 nM, 9.38 nM,
6.69 nM, 2.34 nM, 1.17 nM and 0.59 nM.
doi:10.1371/journal.pone.0033574.g002
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to immobilized PI or TrxPI.
To measure serum concentration of PAA, standard PI was
immobilized on a CM5 sensor chip, being the immobilized protein
in an amount corresponding to 1600 RU. For PAA affinity
determination, the sensor chip was prepared by using lower
concentrations of immobilized antigens (300 RU and 466 RU, for
PI and TrxPI, respectively).
SPR analysis
Concentration of serum proinsulin autoantibodies. A
standard curve (RU vs. antibody concentration previously
determined by RIA) was prepared by using the rabbit anti-
human-PIpolyclonalserum. Theconcentrationsused were:75 nM,
37.50 nM, 18.75 nM, 9.38 nM, 6.69 nM, 2.34 nM, 1.17 nM and
0.59 nM. On the other hand, sera from PAA positive patients were
diluted K, J and
1/8 in running buffer (0.14 M NaCl, 2.7 mM
KCl, 1.5 mM KPO4H2, 8.1 mM Na2PO4H, pH 7.4, 0.05%
Tween 20), and samples were injected over 120 s. The binding
rates were measured after 120 s in running buffer. After each
antigen-antibody interaction, a regeneration step was carried out
using 10 mM glycine-HCl, pH 1.5. All sensorgrams were corrected
by subtracting the signal from the reference flow cell. For each
patient the concentration of PAA was determined by comparison to
the standard curve. All experiments were carried out at 25uC with a
flow rate of 10 ml/min.
Analysis of serum proinsulin autoantibodies affinity. To
evaluate the affinity of PAA, each patient’s serum was used pure or
diluted K, J and
1/8 in running buffer. In either case these
starting samples were diluted K with CM dextran and NaCl to a
final concentration of 1 mg/ml and 0.35 M, respectively, in order
to eliminate the nonspecific reaction. Each sample was injected
over 300 s and the binding rate in running buffer was measured
after 300 s. Assays were carried out at 20uC using a flow rate of
10 ml/min. The association rate constant (k1), the dissociation rate
constant (k21), and the equilibrium constant (Ka), were calculated
from the sensorgrams analysis using the BIA-evaluation software.
Statistical analysis. Data are presented as median and
range (min-max). Differences between groups were evaluated by
the Mann-Whitney U-Test for comparison of the results derived
from childhood-onset and adult-onset diabetic group samples. P
values less than 0.05 were considered as significant. Correlation
between Ka values obtained with immobilized PI or TrxPI was
assessed by standard linear regression.
Results
Proinsulin antibodies parameters
Concentration of proinsulin autoantibodies in sera. The
rabbit polyclonal anti-human-PI serum was first used to perform
the calibration curve (Resonance Units –RU- vs. antibody
concentration) which was later used to quantify PAA in patients’
sera. The antibody concentration of the rabbit polyclonal serum
was previously determined by RIA. Figure 1 shows the dose-
response curves obtained in this fluid phase displacement
experiment in which the incubation lasted until reaching
equilibrium. The parameter K0 (3.34610
8 M
21) was calculated
from the interpolation of 1/K0 at (B/F)0/2 in the plot B/F=f(log
F). The parameter q0 (5.92610
27 M) was calculated from the RIA
plot B/F=f(log dose) where the (B/F)0/2 value intercepting the
abscissa axis equals 1/K0+q0/2 [21]. The standard curve of SPR
analysis was constructed by using the BIAcore
TM software (Fig. 2).
Sera from childhood-onset and adult-onset diabetic patients
were first subjected to RBA to detect the presence of PAA. Those
positive sera were then used for SPR analysis, in order to
characterize PAA concentration (q) and affinity (Ka) parameters
(Fig. 3). In the 28 childhood-onset diabetic patients q ranged from
24.08610
29 M to 243.65610
29 M, median 67.12610
29 M, and
in the 23 adult-onset diabetic patients q ranged from
24.10610
29 M to 318.4610
29 M, median 167.40610
29 M
Figure 3. RBA and SPR results. (A) SD scores, (B) concentration (q)
and (C) affinity constant (Ka) obtained from 28 newly diagnosed type 1
diabetic patients and 23 adult-onset diabetic patients. All the
parameters differed significantly between both groups of patients
(p,0.05).
doi:10.1371/journal.pone.0033574.g003
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the normal human sera.
Affinity of proinsulin antibodies in rabbit and human
sera. To measure the affinity of specific antibodies present in
rabbit serum and patients’ sera, a 1:1 binding protocol was used
for the fitting model. As controls, the median affinity of the rabbit
polyclonal serum for PI and TrxPI was tested in parallel by
a conventional fluid phase RIA (K0-PI=3.34610
8 M
21,
K0-TrxPI=1.70610
8 M
21) and SPR analysis (Ka-PI=
2.48610
8 M
21,K a-TrxPI=2.01610
8 M
21). The affinity of PI
antibodies measured by both procedures was in reasonable
agreement, either using PI or TrxPI.
Figure 4 shows representative examples of sensorgrams
obtained for samples from a childhood-onset diabetic patient (a)
and an adult-onset diabetic patient (b) at 3 serum dilutions.
In childhood-onset diabetic patients, the Ka-PI ranged from
4.45610
4 M
21 to 5.62610
8 M
21 and Ka-TrxPI 5.90610
4 M
21 to
5.18610
8 M
21. In patients with adult-onset diabetes, Ka-PI ranged
from 6.78610
4 M
21 to 1.36610
8 M
21 and Ka-TrxPI ranged from
4.52610
4 M
21 to 1.83610
8 M
21. The median Ka-PI and Ka-TrxPI
values were significantly higher in the childhood-onset diabetes
group than in the adult-onset diabetes group (3.50610
7 M
21 vs
0.84610
7 M
21, 4.65610
7 M
21 vs 0.72610
7 M
21 respectively;
p,0.05) (Fig. 3c, Table 1 and Table S1).
Besides, when injecting sera to flow cell immobilized with either
PI or TrxPI, there was a satisfactory correlation between Ka
values, with r
2=0.80 (Fig. 5).
In order to evaluate the presence of antibodies to Trx in patients
sera, a high sensitive chemiluminescence assay was performed
(Supplemental Material and Methods S2). With this assay we have
demonstrated that there were not IgG binding to Trx in the 51
patients sera studied (Supplemental Results S1 and Figure S1).
Discussion
The first detectable sign of emerging beta cell autoimmunity
during the preclinical asymptomatic period is the appearance of
diabetes-related autoantibodies. For example, IAA have been
shown to predict type 1 DM and to assist in the diagnosis of the
disease [22,23,24]. IAA are detected in 43–70% of newly
diagnosed type 1 diabetic patients [25,26], but are most frequent
and found at higher levels in young children [27,28,29].
There is no marker that allows to identify the IAA-positive
children who will eventually become positive for multiple diabetes-
related autoantibodies. Sustained or repeated antigen exposure
results in a switch from IgM to IgG production, and subsequent
exhaustion of antigen leads to the selection of clones that produce
high-affinity antibodies to the antigen [30,31]. Therefore, affinity
Figure 4. Representative sensorgrams. Panel (A): sera from a childhood-onset diabetic patient and panel (B): sera from an adult-onset diabetic
patient.
doi:10.1371/journal.pone.0033574.g004
Table 1. Comparison of antigen-antibody interaction parameters: Standard Deviation Score (SDs) of signals obtained by RBA;
antibody concentration (q) and affinity (Ka) calculated by BIAevaluation software analysis (BIAcore
TM).
SDs q (10
29 M) Ka-PI (10
6 M
21)K a-TrxPI (10
6 M
21)
Patients Median Range (min-max) Median Range (min-max) Median Range (min-max) Median Range (min-max)
Childhood-onset 9.49 3.44–45.96 67.12 24.08–243.70 35.0 0.04–562.0 46.45 0.06–518.0
Adult-onset 5.04 3.10–49.60 167.4 24.10–318.40 8.35 0.07–136.0 7.16 0.05–183.0
The analyses were carried out on 28 childhood-onset and 23 adult-onset diabtetic patients.
All the parameters differed significantly between both groups of patients (p,0.05).
doi:10.1371/journal.pone.0033574.t001
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may be useful in staging the preclinical phase of type 1 DM. IAA
affinity was previously measured in IAA-positive children from the
prospectively followed BABYDIAB cohort [32]. The findings in
these children who are followed during infancy indicate that IAA
affinity is fixed relatively early in the autoimmune response, that it
distinguishes IAAs with different epitope reactivity, and that it
identifies IAA-positive children who will progress to multiple
autoantibodies. Besides, Achenbach et al. [8] demonstrated that
high affinity IAA were reactive to proinsulin, and Bo ¨mher et al.
[33] found that PAA have a higher association with type 1 DM
than IAA. However, we reasoned that concentration and affinity
of autoantibodies define the level of such humoral response, so it
may be important to determine both parameters for a better
expression of the results. In this sense, the method based on the
SPR technique described herein is an interesting approach for
attaining this goal.
To calculate q and Ka of specific sera, the following sequence
was performed: 1) sera from childhood-onset and adult-onset
diabetic patients were subjected to reference RBA to detect the
presence of PAA, and PAA positive sera were selected for the SPR
analysis; 2) q of specific autoantibodies was determined by the use
of a calibration curve; and 3) once q was known, Ka was
determined by a kinetic procedure.
Because the immobilization of proteins on CM5 sensor chip is
based on covalent binding between carboxyl groups of the chip
surface and amino groups of the proteins, we decided to use as
antigen a recombinant proinsulin fused to thioredoxin (TrxPI)
produced in our laboratory. The goal of this approach was to
improve the orientation of PI assuring that all epitopes were
exposed to antibodies. In order to verify whether TrxPI is a useful
tool for this assay, standard PI was also immobilized on another
cell, and the results obtained with both proteins were compared.
As shown in figure 5, there was a good correlation (r
2: 0.80)
between both immobilized antigens. Furthermore, some of the
evaluated sera interact with higher affinity against TrxPI than
against PI, reconfirming our assumption of an improved
orientation of specific epitopes.
When analyzing comparatively samples from childhood-onset
diabetic patients versus adult-onset diabetic patients the values
obtained by conventional RBA were higher for the former group
(SDs median 9.49 vs. 5.04). However, after SPR analysis, the
childhood-onset diabetic patients presented lower PAA concen-
trations and higher affinities than the adult-onset diabetic group.
These results are consistent with those obtained from solution
RBA methods where the binding can be directly related to the
intrinsic affinity of the antibody [21] (Fig. 3). On the other hand,
the lower affinity values in adult-onset diabetic patients suggest a
different etiopathogenic pathway associated to this slowly
progressive form of autoimmune diabetes. In fact, a different
autoantigen driving process must be involved in affinity matura-
tion of IAA/PAA response in adult-onset diabetic patients since
the lower affinity of their antibodies, as compared to those found
in their type 1 diabetic counterparts, does not agree with their
longer clinical course. All these data, altogether with the clinical
differences, the dissimilar markers profile and the genetic
background, suggest that there is a distinct autoimmune process
involved in childhood-onset and adult-onset diabetic patients.
In conclusion, we have developed an immunoassay for the fast
quantitation of PAA concentration and affinity in sera using the
SPR technique. This technology has been shown to be useful for
the characterization of PAAs parameters, q and Ka,a sa n
alternative to RIA, with high versatility and reproducibility
associated to low occupational and environmental risk. In
addition, the method offers a high analytical capacity in terms of
sensitivity and time-saving.
Although this methodology is not eligible for routine marker
screening, it may be advantageous in programs including
longitudinal studies of first degree relatives of diabetic patients
with demonstrable autoimmunity, specially when the conventional
approach for determining positivity or negativity of humoral
markers is not conclusive. Furthermore, a relevant contribution of
this work is the application of the SPR technology to the indirect
study of the etiopathogenesis of DM in patients with different
clinical features, where the knowledge of autoantibodies param-
eters may allow to characterize more accurately the underlying
autoimmune process against islet beta cells.
Supporting Information
Materials and Methods S1 Expression vector of TrxPI.
(DOC)
Materials and Methods S2 Thioredoxin antibodies detection
by Chemiluminescence Assay.
(DOC)
Results S1 Thioredoxin antibodies detection by Chemilumines-
cence Assay.
(DOC)
Figure S1 S.D. score (SDs) for the binding of Trx to control
subjects (n=40), positive control (polyclonal serum anti-Trx
diluted 1/10000) and diabetic patients (n=51) obtained by
Chemiluminescence Assay. The cut-off value for the assay is
indicated by a dotted line.
(TIF)
Table S1 Concentration (q) and affinity (Ka) results obtained by
SPR and RBA from 51 diabetic patients.
(DOC)
Figure 5. Correlation between Ka obtained using TrxPI or PI in
SPR assays. Ka results were achieved by SPR using either TrxPI or PI as
the immobilized antigen on sensor chip. The regression slope was
0.8660.07 and the correlation coefficient (r
2) was 0.80.
doi:10.1371/journal.pone.0033574.g005
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